Gastroenterology

Adapt Faster,
Execute Better

With early clarity and disciplined execution, Caidya helps you define strategy, reduce operational strain, and move your gastroenterology (GI) clinical research at the speed of science.

Navigate Gastroenterology Complexity

GI clinical development is growing more complex as standards of care evolve, biologic sequencing expands, and metabolic and immunologic pathways increasingly overlap. But complexity doesn’t scare us.

We flex to shifting GI standards of care, support complex patient populations with varied treatment histories, and apply an integrated medical and operational model that prioritizes patient safety, so you can:

Plan Smarter

With early input on trial design and feasibility, we help you reduce risk and avoid delays from burdensome study designs.

Move Faster

Expect coordinated execution across medical monitoring, operations, data, and regulatory functions

Find the Right Patients

Improve enrollment speed and meet critical milestones with our targeted site selection, data-driven recruitment, biomarker screening, and access to diverse populations.

Meet Regulatory Expectations

We align protocols with global regulations and support long-term follow-up through strong site engagement, patient retention strategies, and robust safety monitoring.

Your Solution to
Long-Term GI Challenges

We help you overcome enrollment challenges and address evolving real-world treatment trends by:

Incorporating Early Signals

Slow disease progression won’t slow your trial because we apply early signals to help coordinate and refine endpoint strategies, select responsive subpopulations, and guide regulatory discussions.

Reducing Patient Burden

We sustain your trial’s enrollment with a patient-centric approach that considers visit schedules, integrates noninvasive endpoints and biomarkers when appropriate, and consolidates procedures to minimize biopsies and repetitive tests.

Optimizing Recruitment

GI enrollment struggles won’t bother you when we leverage real-world data, select experienced sites, target appropriate patient populations, and align trial designs with evolving standards of care and prior therapy exposure.

Our Gastroenterology Clinical Research Services

  • Full-service GI clinical trial support from start-up through closeout
  • Management of studies with intensive procedures and monitoring requirements
  • Global execution adapted to regional differences in care pathways and patient access
  • Clinical trial feasibility and protocol review to help decrease patient burden during clinic visits

How Can Caidya Help Your
Gastroenterology Clinical Research?

When you partner with Caidya for GI research, you get:

  • Experience from our demonstrated, consistent delivery of GI trials with procedural and endpoint complexity
  • Cross-therapeutic insights to address the overlap of GI with metabolic and immune-mediated diseases
  • Expert support based in our experience across a wide range of rare and non-rare gastroenterological diseases
  • Coordination across all aspects of your GI program, from strategy and trial design to regulatory filing, to deliver the data you need

Frequently Asked Questions
in Gastroenterology Clinical Research

How do evolving standards of care impact GI trial design?

As standards of care shift, gastroenterology trial designs must adapt to remain relevant and ethical. This can affect comparator selection, inclusion criteria, endpoints, and positioning within treatment sequences, stressing the importance of flexible protocols and a forward-looking strategy.

What are the benefits and limitations of noninvasive endpoints and biomarkers?

Noninvasive measures can reduce patient burden, improve recruitment, and enable more frequent monitoring. However, these measures may lack validation, sensitivity, or regulatory acceptance compared to traditional endpoints, requiring thoughtful integration into study design.

How do you balance regulatory rigor with patient burden in GI trials?

Effective balance comes from designing studies that meet regulatory expectations while minimizing unnecessary procedures. This includes leveraging validated biomarkers, optimizing visit schedules, and focusing on endpoints that deliver meaningful data without overburdening sites and patients.

Which GI clinical trials have you supported?

At Caidya, our experience in gastroenterology covers a wide range of rare and non-rare diseases:

  • Multiple etiologies of constipation
  • Diarrhea
  • GI ulcers, including duodenal, peptic, and hemorrhagic
  • Anal fissures
  • Gastroesophageal reflux and esophagitis
  • Gastroparesis
  • Hepatitis, including viral (Hep B and Hep C)
  • Inflammatory bowel disease
    • Ulcerative colitis
    • Crohn’s disease
  • Irritable bowel syndrome
  • Mucositis
  • Pancreatitis
  • Vomiting (emesis)
  • Nutritional disorders and supplementation, both enteral and parenteral
  • Orphan and rare diseases, including:
    • Eosinophilic esophagitis
    • Behcet’s syndrome
    • Urea cycle disorder
    • Prader-Willi syndrome